scholarly journals LOSS ofMrp1alters detoxification enzyme expression in a tissue- and hormonal-status-specific manner

2012 ◽  
Vol 33 (8) ◽  
pp. 766-773 ◽  
Author(s):  
Jeffrey C. Sivils ◽  
Tiffany M. Ancrum ◽  
Lisa J. Bain
2011 ◽  
Vol 76 (3) ◽  
pp. C454-C461 ◽  
Author(s):  
Melissa G. Robbins ◽  
Gaby Andersen ◽  
Veronika Somoza ◽  
Bruce D. Eshelman ◽  
David M. Barnes ◽  
...  

1991 ◽  
Vol 124 (3) ◽  
pp. 322-330 ◽  
Author(s):  
Arleen L. Sawitzke ◽  
William D. Odell

Abstract. High-affinity LH/hCG binding sites have been identified in both porcine and rabbit uteri. We have now identified these binding sites in rat uteri. We have assessed the binding site specificity and modulation and have searched for binding sites for a related glycoprotein. Radioreceptor assays were performed with membrane homogenates of uterine tissue, and were analysed for binding site specificity, affinity, and capacity. The rabbit and rat LH/hCG binding sites did not bind human TSH or human FSH. Rabbit uterine tissue contained no binding sites for FSH, as determined with 125I-labelled FSH and unlabelled FSH. Pretreatment of rabbits with hCG decreased their uterine binding site capacity from 1.30±0.29 to 0.46±0.01 fmol/mg protein. Pretreatment of castrated rabbits with estrogen or estrogen combined with progesterone did not alter the binding site affinity or capacity. In rats, the uterine binding site number was shown to vary inversely with the serum LH concentration and directly with the ovarian LH/hCG bindig site number during the estrus cycle. Hypophysectomy resulted in a significant increase in uterine binding site capacity in rats. Estrogen treatment prevented this hypophysectomy-induced increase. The function of these LH/hCG binding sites remains uncertain; however, the lack of binding sites for a related glycoprotein and the modulation of these binding sites by hormonal factors strengthen the concept that uterine tissue might respond in a specific manner to direct LH/hCG stimulation.


Nitric Oxide ◽  
2007 ◽  
Vol 17 ◽  
pp. 18
Author(s):  
C.J. MacDonald ◽  
P. Sienkiewicz ◽  
S.E. Bass ◽  
D.D. Wink ◽  
G.C. Yeh

Swiss Surgery ◽  
2003 ◽  
Vol 9 (2) ◽  
pp. 55-62 ◽  
Author(s):  
Bartanusz ◽  
Porchet

The treatment of metastatic spinal cord compression is complex. The three treatment modalities that are currently applied (in a histologically non-specific manner) are surgery, radiotherapy and the administration of steroids. The development of new spinal instrumentations and surgical approaches considerably changed the extent of therapeutic options in this field. These new surgical techniques have made it possible to resect these tumours totally, with subsequent vertebral reconstruction and spinal stabilization. In this respect, it is important to clearly identify those patients who can benefit from such an extensive surgery. We present our management algorithm to help select patients for surgery and at the same time identifying those for whom primary non-surgical therapy would be indicated. The retrospective review of surgically treated patients in our department in the last four years reveals a meagre application of conventional guidelines for the selection of the appropriate operative approach in the surgical management of these patients. The reasons for this discrepancy are discussed.


Sign in / Sign up

Export Citation Format

Share Document